Disease ⇒ Breast cancer ⇒ Cancer {40000376}
Type: | Disease |
---|---|
Definition: | Breast cancer |
Parent: |
Initialisation date: | [ ] |
---|---|
Other Terms: | [ ] |
MedDra ID: | 10006187 |
---|---|
MedDra Level: | pt |
ICD: | [ ] |
Category: | [ ] |
Zone: | [ ] |
Mechanism: | [ ] |
Notes:
[ ]
References Notes
[ ]
Shared Reference Notes
- [1.8]
- Cadaverine as a biogenic amine is formed through the direct decarboxylation of L-lysine.
- It is reported that cadaverine biosynthesis is reduced in the gut in early-stage BC, resulting in lower production of an anti-cancer bacterial metabolite and reduced BC invasion - - Lithocholic acid can inhibit BC progression, epithelial-mesenchymal transition, and metastasis via activation of nuclear factor erythroid 2-related factor 2 (NRF2) and other proteins involved in the antioxidant defense system.
- - Propionate, acetate, and butyrate are the three most predominant SCFAs and are well-known modulators for cell invasion and apoptosis in BC
- - The abundance of Akkermansia muciniphila, as a key player of propionate production, is associated with the richness of the gut microbiota in patients with BC
- - Intestinal bacteria can turn some plant lignans such as flaxseed, sunflower, caraway, pumpkin, legumes, and soybean, into mammalian lignans with protective effects against BC.
- High consumption of raw vegetables showed a significant protective effect against BC risk. - - Enterolactone may act as a selective modulator of estrogen signaling and may be associated with lowering the risk of BC.
- - Overuse of antibiotics might reduce the plasma level of lignan enterolactone; therefore, it might directly affect the microbiome populations and increase the BC risk
- - Estrobolome, the bacterial gene mass in the human intestine, the products of which take part in estrogens metabolism, may increase the risk of estrogen receptor-positive BC in postmenopausal females.
- Changes in gut microbiome composition may lead to the estrogen metabolism alternation and affect the BC risk. - - The proportions of Blautia and F. Prausnitzii and absolute numbers of Blautia and Bifidobacterium species in the gut microbiome are directly correlated with the clinical stage of BC.
- For instance, patients with stage 1 BC had a lower number of gut Blautia sp. in comparison with the ones with stage grade 3 - [1.9]
- Antibiotic-induced perturbation of the gut microbiota > increases tumor progression in multiple BrCa mouse models > increased number of cells with a stromal signature in tumors > increased abundance of mast cells in the tumor stromal regions.
- Re-supplementation of antibiotic-treated mice with Faecalibaculum rodentium > restored tumor growth to control levels
- Mast cell stabilizer, cromolyn > decreases tumor growth only in antibiotic treated animals - [1.11]
- Fucoidan > increasing the diversity of the intestinal flora composition and increasing the Bacteroidetes/Firmicutes phylum ratio > can restore intestinal wall damage in mice > prevent the occurrence of breast cancer - - H2S at a safe and nontoxic concentration can protect not only healthy cells, such as neurons, but also cancerous cells from apoptosis.
- In a variety of cancers, including ovarian cancer, oral cancer, thyroid cancer, colon cancer, breast cancer, etc., the upregulation of H2S-producing enzyme CBS > can enhance the proliferation ability of cancer cells and make cancer cells more sensitive to it - [1.12]
- Permutation testing with FDR control revealed taxa differences for fat% in Firmicutes, Bacilli, Bacillales, Staphylococcaceae and genus Staphylococcus, and fibrosis% in Firmicutes, Spirochaetes, Bacilli, Bacillales, Spirochaetales, Proteobacteria RF32, Sphingomonadales, Staphylococcaceae, and genera Clostridium, Staphylococcus, Spirochaetes, Actinobacteria Adlercreutzia.